Credit Suisse assumes its Outperform rating on Vivus VVUS and lowers its price target from $36 to 34.
Credit Suisse notes, "If approved, Qnexa is certain to carry a risk management program ("REMS"); the impact of this on Qnexa's revenues is uncertain. We suspect the REMS may impact both the launch trajectory and peak - we are cutting our US revenue forecasts through 2020. Other changes to our model include: assuming 100% of EU revenues (vs. only a 20% royalty previously) and higher SG&A in 2014 and beyond as VVUS scales up a large GP field force after the initial launch. These changes are outlined in Exhibits 1-2. The net result is our target price goes to $34 (from $36)."
CP closed at $22.43 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in